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The gene insulin-like growth factor binding protein 3 (IGFBP3) has been previously 
shown to be a primary vitamin D3 receptor (VDR) target containing three vitamin D3 
response elements (VDREs) in its promoter. It is up-regulated by the natural VDR ligand, 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), and is also a mediator for 1α,25(OH)2D3-
mediated growth inhibition. In this study, non-malignant MCF-10A human mammary cells 
showed cyclical IGFBP3 induction with 60 min periodicity after detailed time course 
stimulation with 1α,25(OH)2D3. Cycling of mRNA was the outcome from ligand-
dependent VDR association to all VDREs and histone 4 acetylation of the proximal 
VDREs. Interestingly, these actions were not observed in response to treatment with the 
1α,25(OH)2D3 analog Gemini, where IGFBP3 mRNA expression was linear and more 
prominent. To study this process in more detail, gene expression profiles of every of the 11 
histone deacetylase (HDAC) genes were measured after stimulation with both ligands. 
HDACs are important mediators for chromatin condensation and transcriptional repression 
and therefore they also play a role in transcriptional cycling. Interestingly, only the 
HDAC4 and HDAC6 genes responded to 1α,25(OH)2D3 treatment, while none of them to 
Gemini. In addition, transcriptional cycling was eliminated after combined mRNA 
silencing of both HDAC4 and HDAC6. Furthermore, HDAC4 and HDAC6 showed 
cyclical association with VDREs in response to VDR ligands. In conclusion, 
1α,25(OH)2D3 regulates IGFBP3 expression in a cyclical fashion with cyclical recruitment 
of VDR, HDAC4 and HDAC6 to VDREs on IGFBP3 promoter. Because Gemini has 
stronger interactions with VDR, it does not induce transcriptional cycling, which results in 
stable IGFBP3 mRNA induction. 
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ABBREVIATIONS 
 
1α,25(OH)2D3  1α,25-dihydroxyvitamin D3 
25(OH)D3  25-hydroxyvitamin D3 
ALS   acid-labile subunit  
CDK   cyclin-dependent kinase 
ChIP   chromatin immuno-precipitation 
CoA   co-activator 
CoR   co-repressor 
CYP   cytochrome P450 
CYP24A1  cytochrome P450, family 24, subfamily A, polypeptide 1 gene 
CYP27A1  cytochrome P450, family 27, subfamily A, polypeptide 1 gene 
CYP27B1  cytochrome P450, family 27, subfamily B, polypeptide 1 gene 
DBD   DNA-binding domain 
DBP   vitamin D-binding protein 
DMEM  Dulbecco’s modified Eagle’s medium 
DR   direct repeat 
ER   everted repeat 
FAM   6-carboxyfluorescein 
FBS   fetal bovine serum 
acH4   acetylated histone H4 
HAT   histone acetyltransferase 
HDAC   histone deacetylase 
IGF    insulin-like growth factor 
IGF-I   insulin-like growth factor-I 
IGF-II   insulin-like growth factor-II 
IGF-IR  type I insulin-like growth factor receptor 
IGF-IIR  type II insulin-like growth factor receptor 
IGFBP   insulin-like growth factor binding protein 
IR   inverted repeat 
LBD   ligand-binding domain 
LBP   ligand-binding pocket 
MS   multiple sclerosis 
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NR   nuclear receptor  
PBS   phosphate buffered saline 
PTH   parathyroid hormone  
RA   rheumatoid arthritis  
pRb   retinoblastoma protein 
RE   response element 
RPLP0  ribosomal protein, large, P0 
RT-qPCR  real-time quantitative PCR 
RXR   retinoid X receptor 
siRNA   small inhibitory RNA  
Th1   T helper type I 
Th2   T helper type II 
TSS   transcription start site 
TGF-β   transforming growth factor-β 
VDR   vitamin D3 receptor 
VDRE   vitamin D3 response element 
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1 INTRODUCTION 
 
The pro-hormone vitamin D3 is produced in skin or taken up from diet. It is converted in 
the liver and the kidneys to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), which is the 
biologically active form of vitamin D3 (Haussler et al., 1998). The main role of 
1α,25(OH)2D3 is in regulation of calcium and phosphate homeostasis and bone 
mineralization, but it also has important pro-apoptotic and anti-proliferative effects in 
regulation of cell growth (DeLuca, 2004). 1α,25(OH)2D3 mediates its effects on gene 
regulation by activating the vitamin D3 receptor (VDR) (Sutton & MacDonald, 2003). 
Circulating 1α,25(OH)2D3 levels are tightly regulated, including the regulation of 
1α,25(OH)2D3 synthesis and feedback-mediated degradation (Haussler et al., 1998). 
 
VDR is a member of the nuclear receptor (NR) superfamily and is the only mediator for 
genomic actions of 1α,25(OH)2D3. Binding of 1α,25(OH)2D3 activates VDR by inducing a 
conformational change of its ligand-binding domain (LBD). Ligand-activated VDR 
functions as a heterodimer with retinoid X receptor (RXR) and acts as a direct regulator of 
target gene expression by binding to vitamin D3 response elements (VDREs) within the 
regulatory region of VDR target genes (Toell et al., 2000). During transcriptional 
activation, ligand-activated VDR recruits co-activators (CoAs). While unliganded, VDR 
associates with co-repressors (CoRs) and histone deacetylases (HDACs) that are removing 
histone acetylation (Polly et al., 2000). Generally, acetylation of histones mediates 
transcriptional activation through chromatin decondensation, while deacetylation mediates 
transcriptional repression through chromatin condensation (Wegel & Shaw, 2005). 
Transcription induced by NRs has recently been shown to be a cyclical process, where 
altering states of repressing, activation and initiation take place (Degenhardt et al., 2009). 
This process regulates tightly the transcriptional process via cyclical control of mRNA 
synthesis. 
 
Because therapeutic levels of 1α,25(OH)2D3 cause hypercalcemic toxicity, thousands of 
synthetic 1α,25(OH)2D3 analogs are designed to improve medically interesting features of 
1α,25(OH)2D3 and to decrease calcemic toxicity (Carlberg & Mouriño, 2003). An 
interesting analog is Gemini, which is a strong VDR agonist carrying two side chains, 
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while vitamin D3 has only one. In addition, Gemini can bind VDR in a two different 
conformations (Väisänen et al., 2003; Molnár et al., 2006). In one conformation Gemini 
acts as an agonist, but in another conformation as an inverse agonist. 
 
In this study, detailed time course experiments showed cyclical induction of the IGFBP3 
gene in response to 1α,25(OH)2D3 stimulation, but not in response to Gemini. 
Transcriptional cycling resulted from cyclical recruitment of VDR on VDREs at the 
IGFBP3 promoter. In addition, the genes HDAC4 and HDAC6 were up-regulated in a 
cyclical fashion with 1α,25(OH)2D3, but not with Gemini. Interestingly, cycling of 
IGFBP3 expression was diminished, when HDAC4 and HDAC6 expressions were down-
regulated by siRNAs. This observation establishes the significant roles of HDAC4 and 
HDAC6 for the cyclical regulation of VDR target gene expression induced by the natural 
ligand. In addition, HDAC4 and HDAC6 showed VDR-ligand induced association with 
VDRE regions. In conclusion, up-regulation of IGFBP3 mRNA expression in response to 
1α,25(OH)2D3 is an interactive process, where cyclical recruitment of VDR, HDAC4 and 
HDAC6 to VDRE-containing promoter regions results in a cyclical mRNA accumulation. 
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2 LITERATURE REVIEW 
 
2.1 1α,25(OH)2D3 
 
2.1.1 Vitamin D3 metabolism 
 
Vitamin D3 is a fat-soluble pro-hormone and is produced in skin or taken up from diet. Pre-
vitamin D3 is produced in skin through UVB-irradiation of 7-dehydrocholesterol in a 
multi-step process. Additionally, vitamin D3 can be taken up from diet, such as dairy 
products, fish or eggs, but natural dietary sources are the minor component compared to 
the production in skin (Hollis, 2005). Vitamin D3 deficiency is very common and 
worldwide problem. The main reasons are that UVB radiation reduces towards northern 
latitudes and that skin pigmentation reduces vitamin D3 production (Lips, 2006). In 
addition, personal and cultural behavior affects largely to UVB exposure. To prevent 
vitamin D3 deficiency, vitamin D3 is added to fortified milk products in many countries 
and different products of supplementary vitamin D3 are commonly available for 
consumers. 
 
Vitamin D3 is hydroxylated by liver 25-hydroxylases, encoded by the cytochrome P450 
(CYP) genes CYP27A1 or CYP2R1, to 25-hydroxyvitamin D3 (25(OH)D3) that is an 
inactive form of vitamin D3, and stored in the liver (Deeb et al., 2007). In general, serum 
25(OH)D3 levels represents the whole body’s vitamin D3 status and low serum 25(OH)D3 
levels are a good marker of vitamin D3 deficiency (Garland et al., 2006). 25(OH)D3 is 
subsequently hydroxylated mainly in kidneys to 1α,25(OH)2D3 by mitochondrial 1α-
hydroxylase encoded by the gene CYP27B1 (Haussler et al., 1998). This active form of 
vitamin D3 is the actual hormone and mediates most of the actions of all vitamin D3 
derivates. Both 1α,25(OH)2D3 and 25(OH)D3 can be 24-hydroxylated to the metabolites 
1α,24,25(OH)3D3 and 24,25(OH)2D3, respectively, which leads to catabolism of these 
metabolites. 24-hydroxylation is mediated by 25-hydroxyvitamin D3 24-hydroxylase (24-
OHase), encoded by gene CYP24A1. In the circulation, all vitamin D3 metabolites are 
bound to vitamin D-binding protein (DBP), which binds with high affinity those 
metabolites and has a high homology to albumin (Lips, 2006). All metabolic steps are 
presented in Figure 1. 
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Figure 1. Vitamin D3 metabolism (Adapted from Deeb et al., 2007). Vitamin D3 is produced in skin or 
obtained from diet. Circulating pre-vitamin D3 is bound to DBP and is converted to the active metabolites, 
25(OH)D3 and 1α,25(OH)2D3, by the liver and the kidneys. Parathyroid hormone (PTH) induces 
1α,25(OH)2D3 production and 24-OHase mediates degradation of both 1α,25(OH)2D3 and 25(OH)D3. 
 
The 1α,25(OH)2D3 metabolism is tightly regulated to maintain constant 1α,25(OH)2D3-
levels. Parathyroid hormone (PTH) induces renal CYP27B1 expression, which increases 
1α,25(OH)2D3 production. In contrast, increasing levels of 1α,25(OH)2D3 repress 
CYP27B1 expression and induce strongly CYP24A1 expression, which mediates reduced 
production and increased degradation of active vitamin D3 metabolites (Haussler et al., 
1998). There is also an extra-renal tissue-specific regulation of CYP27B1 expression, 
which reveals both regulation and function of 1α,25(OH)2D3 metabolism in a tissue-
specific manner (Zehnder et al., 2001).  
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consist of CYP24A1 (REF. 60) (encoding 24-OHase), 
BGLAP61 (osteocalcin; expressed in bone osteoblasts), 
and CDKN1A62 (which encodes the cyclin depend-
ent kinase (CDK) inhibitor p21). Those repressed 
by 1A,25(OH)2D3 include PTH53. Although VDREs 
are traditionally thought to occur in the promoter 
regions of the target genes, a DR3-type VDRE was 
recently identified in exon 4 of the growth arrest 
and DNA-damage-inducible (GADD45) gene63.
1A,25(OH)2D3-mediated repression or activation of 
many proto-oncogenes or tumour-suppressor genes 
is described in normal and tumour tissues62,64–67;
however, only a few such genes contain VDREs in the 
promoter regions and are under the direct transcrip-
tional control of 1A,25(OH)2D3, such as CDKN1A62
and CCNC (which encodes cyclin C, containing a 
DR4-type VDRE)65. This suggests that 1A,25(OH)2D3
exerts many of its effects indirectly by modulating 
signalling cascades or by unknown nongenomic 
mechanisms (FIGS 2,3).
Nongenomic action of 1A,25(OH)2D3. Nongenomic 
actions mediated by 1A,25(OH)2D3 are rapid and not 
dependent on transcription. However, nongenomic 
signalling may indirectly affect transcription through 
cross-talk with other signalling pathways68,69. Although 
there is no agreement on how the nongenomic actions 
are initiated, data suggest that these effects begin at the 
plasma membrane and involve a non-classical membrane 
receptor (memVDR; FIG. 2) described in intestinal caveo-
lae70, and a 1A,25(OH)2D3-membrane-associated rapid-
response steroid binding protein (1A,25D3-MARRS) 
isolated from chick intestinal basal-lateral membrane71.
The most well-described nongenomic effect of 
1A,25(OH)2D3 is the rapid intestinal absorption of Ca2+
(REF. 72). Binding of 1A,25(OH)2D3 to the proposed mem-
brane receptor can result in the activation of numerous 
signalling cascades68,69 (FIG. 2). Activation of these signalling 
cascades, such as protein kinase C (PKC), can result in the 
rapid opening of voltage-gated Ca2+ channels and an increase 
in intracellular Ca2+ (REF. 73), which may subsequently 
Figure 1 | Vitamin D metabolism. Photochemical synthesis of vitamin D3 (cholecalciferol, D3) occurs cutaneously 
where pro-vitamin D3 (7-dehydrocholesterol) is converted to pre-vitamin D3 (pre-D3) in response to ultraviolet B 
(sunlight) exposure. Vitamin D3, obtained from the isomerization of pre-vitamin D3 in the epidermal basal layers or 
intestinal absorption of natural and fortified foods and supplements, binds to vitamin D-binding protein (DBP) in the 
bloodstream, and is transported to the liver. D3 is hydroxylated by liver 25-hydroxylases (25-OHase). Th  resultant 
25-hydroxycholecalciferol (25(OH)D3) is 1A-hydroxylated in the kidney by 25-hydroxyvitamin D3-1A-hydroxylase 
(1A-OHase). This yields the active secosteroid 1A,25(OH)2D3 (calcitriol), which has different effects on various target 
tissues23. The synthesis of 1A,25(OH)2D3 from 25(OH)D3 is stimulated by parathyroid hormone (PTH) and suppressed by 
Ca2+, Pi and 1A,25(OH)2D3 itself. The rate-limiting step in catabolism is the degradation of 25(OH)D3 and 1A,25(OH)2D3
to 24,25(OH)D3 and 1A,24,25(OH)2D3, respectively,which occurs through 24-hydroxylation by 25-hydroxyvitamin D 24-
hydroxylase (24-OHase), encoded by the CYP24A1 gene. 24,25(OH)D3 and 1A,24,25(OH)2D3 are consequently excreted. 
The main effects of 1A,25(OH)2D3 on various target tissues are highlighted above.
REVIEWS
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2.1.2 1α,25(OH)2D3 actions on bone 
  
An important role of 1α,25(OH)2D3 is in regulation of calcium and phosphate homeostasis 
and of bone mineralization (DeLuca, 2004; Lips, 2006). It is the only known hormone that 
directly induces i) production of proteins being involved in active intestinal calcium intake 
and ii) intestinal phosphate absorption (Wasserman & Fullmer, 1995; DeLuca, 2004). PTH 
production is actively induced in response to decreased calcium levels, which leads to 
production of more 1α,25(OH)2D3 and thus increased calcium levels. In cases when 
environmental calcium is not sufficiently available, both 1α,25(OH)2D3 and PTH induce 
bone resorption and reduce renal calcium excretion to maintain adequate serum calcium 
level (Suda et al., 2002). In contrast, increased calcium levels decrease PTH production 
and activate osteoblast formation in the bone. Overall, this regulatory network maintains 
both calcium and 1α,25(OH)2D3 levels in balance, which in turn keeps the formation and 
resorption of bone in balance. In vitamin D3 deficiency or in cases when 1α,25(OH)2D3 
metabolic pathways (such the CYP27B1 gene) are inoperative, calcium resorption from 
bone is increased due to the reduced intestinal intake and increased PTH levels, which can 
lead to osteomalacia or rickets (Lips, 2006). 
 
 
2.1.3 Anti-tumor actions of 1α,25(OH)2D3  
 
In addition to its role in mineral metabolism, it has been shown that 1α,25(OH)2D3 also 
plays important role in cell growth regulation and has anti-proliferative features (Ingraham 
et al., 2008). Furthermore, several epidemiological studies and meta-analyses have shown 
that low serum 25(OH)D3 levels are connected to increased cancer incidents of the breast, 
colon, prostate and ovary and it is believed that adequate levels, in contrast, would offer a 
protective role against these cancers (Ingraham et al., 2008; Garland et al., 2006). In 
addition, overexpression of the CYP24A1 gene has been reported in several type of cancer 
tissues, which leads to reduced anti-cancer effects of 1α,25(OH)2D3 (Deeb et al., 2007). 
 
In breast cancer cells the anti-cancer action of 1α,25(OH)2D3 includes cell cycle arrest and 
induction of apoptosis and differentiation (Welsh, 2007a; Mathiasen et al., 1999; 
Verlinden et al., 1998). However, these anti-cancer features vary between different cell 
and cancer types. In MCF-7 human breast cancer cells 1α,25(OH)2D3 can induce 
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retinoblastoma protein (pRb)-mediated G1/G0 cell cycle arrest by up-regulating gene 
expression of the cyclin-dependent kinase (CDK) inhibitor genes CDKN1A and CDKN1B 
which encode protein p21 and p27 respectively (Verlinden et al., 1998). This leads to 
inhibition of CDK activity, which in turn causes pRb hypophosphorylation and pRb-
mediated cell cycle arrest.  
 
In addition to its capacity to induce cell cycle arrest, 1α,25(OH)2D3 is able to induce 
apoptosis in MCF-7 and T47D cells (Mathiasen et al., 1999). Apoptosis is caused by 
down-regulation of the anti-apoptotic protein Bcl-2 and by translocation of the pro-
apoptotic protein Bax from the cytosol to mitochondria in response to 1α,25(OH)2D3 
treatment. However, overexpression of Bcl-2 is able to prevent this 1α,25(OH)2D3-induced 
apoptosis, which suggests the involvement of the Blc-2 pathway in this process. Moreover, 
Xie et al. (1999) found that in these cell lines 1α,25(OH)2D3 induces growth inhibition by 
down-regulation of the insulin-like growth factor (IGF) signaling pathway, which leads to 
promotion of apoptosis. IGFs are strong anti-apoptotic peptides that mediate their 
mitogenic signals mainly through type I IGF receptor (IGF-IR) (Hwa et al., 1999). In 
addition, overexpression of IGF-IR is one feature of breast cancer cell and high levels of 
circulating IGFs are strongly associated to breast cancer risk (Renehan et al., 2006). 
Furthermore, up-regulation of proteins that are involved in regulating the actions of IGFs, 
such as IGFBPs, is one feature of 1α,25(OH)2D3-mediated growth inhibition in breast 
cancer cells (Colston et al., 1998). IGFBPs will be discussed in more detailed in chapter 
2.4.  
 
However, anti-cancer effects of 1α,25(OH)2D3 do not limit only to growth inhibition of 
cancer cells, but 1α,25(OH)2D3 signaling has also been associated in preventing 
carcinogenesis. 1α,25(OH)2D3 directly regulates key proteins involved in proliferation and 
differentiation of normal mammary cells (Welsh, 2007b). In the mouse mammary gland, 
the VDR is localized mainly in differentiated cells. During pregnancy and lactation, when 
cells undergo differentiation, expression of VDR is increased about 100-fold, while VDR 
knockout mice are undergoing excessive proliferation and impaired apoptosis (Zinser et 
al., 2002; Zinser & Welsh, 2004). In general, 1α,25(OH)2D3 signaling is found to promote 
or maintain the differentiated phenotype of normal mammary cells and also animal models 
have shown that 1α,25(OH)2D3 signaling protects against carcinogenesis of mammary cells 
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(Welsh, 2007a). In addition, several epidemiological studies are consistent with the 
protective role of 1α,25(OH)2D3 in carcinogenesis (Deeb et al., 2007).  
 
 
2.1.4 1α,25(OH)2D3 actions on immunity 
 
1α,25(OH)2D3 signaling has been shown to have potent immunomodulatory effects in both 
innate and adaptive immune cells (Nagpal et al., 2005). VDR is expressed and is inducible 
by 1α,25(OH)2D3 in central immune cells, such as T-cells, monocytes/macrophages and 
natural killer cells (Veldman et al., 2000). In addition, several epidemiological studies 
have shown reduced serum 25(OH)D3 levels in autoimmune diseases such as multiple 
sclerosis (MS), type I diabetes and rheumatoid arthritis (RA) (Nagpal et al., 2005). 
Adequate serum 25(OH)D3 level, especially earlier in life, is suggested to offer protection 
against multiple sclerosis (Munger et al., 2006). Furthermore, VDR-ligands have shown to 
directly inhibit production of IL-12 cytokines by monocytes, which, in turn, leads to 
reduced T helper I (Th1) development without affecting T helper II (Th2) development 
(Mattner et al., 2000). Th1 cells play central role in MS, and reduction of Th1 development 
has been shown to be beneficial in treatment of MS in animal models.  
 
Administration of 1α,25(OH)2D3 has been shown to be protective also in other 
autoimmune diseases. In NOD mice, which are the most widely used animal model for 
type I diabetes, onset of type I diabetes could be prevented by 1α,25(OH)2D3 and its 
synthetic analog administration (Mathieu et al., 1994, 1995). In addition, human study with 
high 1α,25(OH)2D3 administration from 1-year of age resulted in 80 % decreased risk of 
developing type I diabetes later in life (Hyppönen et al., 2001). Synthetic 1α,25(OH)2D3 
analogs also effectively inhibited progression of ongoing type I diabetes in NOD mice 
(Gregori et al., 2002). This inhibition was associated with reduced Th1 infiltration into the 
pancreas, which was consequence from reduced IL-12 production. Furthermore, 
1α,25(OH)2D3 or analog administration promoted improvement in RA symptoms and 
disease activity (Andjelkovic et al., 1999). All these features establish that 1α,25(OH)2D3, 
has an important role in the immune system by mediating Th1 suppression and adequate 
1α,25(OH)2D3 intake may also reduce incidents of central autoimmune diseases.  
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2.2 Vitamin D3 receptor 
 
2.2.1 Overview of nuclear receptors 
 
The VDR belongs to the 48-member superfamily of nuclear receptors (NRs) that are 
ligand-activated transcription factors and regulate gene expression of target proteins 
involved in various processes such as metabolism, reproduction and development 
(McKenna & O’Malley, 2002). In addition, VDR is one of the members of the classic 12 
nuclear receptors that function as endocrine receptors, which bind their ligands with high 
affinity (Chawla et al., 2001) Ligands for NRs can be involved in endocrine signaling, 
such as thyroid and steroid hormones, or lipids involved in fatty acid metabolism (Li et al., 
2003). There is also a group of orphan receptors, which ligands are either unknown or they 
are not ligand-activated at all (Benoit et al., 2006). Because NRs are central regulators of 
various genes, they serve as a good drug targets for numerous diseases such as asthma, 
type 2 diabetes, atherosclerosis and cancer. Structurally NRs share a highly conserved 
DNA-binding domain (DBD) and a structurally conserved carboxy-terminal ligand-
binding domain (LBD) (Carlberg & Molnár, 2006). The DBD contains two conserved zinc 
finger motifs, which bind to specific DNA sequences, known as response elements (RE), 
in a regulatory region of target gene, while LBD contains a ligand-binding pocket (LBP), 
which serves as a binding site for the receptor-specific ligand (Chawla et al., 2001, 
Carlberg & Molnár, 2006). In general, NRs can be considered as molecular switches for 
transcription of those genes that contain response element in their promoter region 
(Carlberg & Polly, 1998). 
 
 
2.2.2 VDR function 
 
VDR is the only mediator of the genomic actions of 1α,25(OH)2D3, is expressed widely 
and can be detected in all human tissues (Carlberg, 2004; Carlberg et al., 2007). Primary 
1α,25(OH)2D3 target genes contain usually several 1α,25(OH)2D3 response elements 
(VDREs), which are formed by two hexameric DNA sequences, core-binding motif, with 
the consensus sequence RGKTSA (R = A or G, K = G or T, S = C or G) (Carlberg & 
Polly, 1998). Furthermore, core-binding motifs can be organized in three different 
 16 
configurations; direct repeat (DR), everted repeat (ER) and inverted repeat (IR), with few 
intervening nucleotides. VDR regulates transcription by binding directly to VDREs 
primary as a heterodimer with RXR (Toell et al., 2000). VDR-RXR heterodimers prefer 
binding to DR-type motifs with 3 intervening nucleotides known as DR3 (Umesono et al., 
1991). However, this is not the only functional VDRE motif and other functional VDRE-
motifs are reported, such as DR4, ER6, ER7, ER8 and ER9 (Schräder et al., 1995; Quack 
& Carlberg, 2000). In addition, VDREs can be located on both DNA strands and also far 
away from transcription start site (TSS). For example, IGFBP3 promoter contains a 
tandem of two VDREs at position -400 and another VDRE in another strand at position -
3350 relative to TSS (Peng et al., 2004; Matilainen et al., 2005). 
 
When unliganded, VDRE-bound VDR-RXR-dimers associate with nuclear co-repressor 
proteins (CoRs), such as NCoR and SMRT, which in turn associate with histone 
deacetylases (HDACs) and keep chromatin in locally condensed and transcriptionally 
repressed state (Polly et al., 2000). Binding of 1α,25(OH)2D3 to the LBP of LBD changes 
the conformation of LBD, which destabilizes the CoR-VDR complex and results in release 
of CoRs and subsequent recruitment of co-activator (CoA) proteins, such as proteins of the 
p160-family (Leo & Chen, 2000). Some CoAs have histone acetyltransferase (HAT) 
activity or are complexed with proteins having such activity and this results in local 
chromatin decondensation (Castillo et al., 1999). Ligand-activated VDR subsequently 
releases CoAs of the p160 family and interacts with those CoAs of mediator complexes, 
such as Med1 (Rachez et al., 1998). The mediator complex is a multi-subunit CoA 
complex and consist of 15-20 proteins, which build a bridge between VDR and basal 
transcription machinery located on the TSS (Rachez et al., 1999). Through these events 
1α,25(OH)2D3-activated VDR can mediate both the modification of chromatin and direct 
regulation of transcription by protein-protein interactions. These ligand-induced actions of 
VDR are in central role in nuclear 1α,25(OH)2D3 signaling and activation of transcription. 
 
As described, transcription mediated by NRs is a dynamic process. In addition, recent 
chromatin immunoprecipitation (ChIP) and mRNA expression studies have shown both 
cyclical promoter activation and mRNA expression mediated by NRs, such as estrogen 
receptor α on the trefoil factor-1 gene, peroxisome proliferater-activated receptor δ on the 
pyryvate dehydrogenase kinase 4 gene and VDR on the CYP24A1 and CDKN1A genes 
(Métivier et al., 2003; Kim et al., 2005; Degenhardt et al., 2009; Saramäki et al., 2009). 
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According to these studies, dynamic nature of transcription is a tightly regulated cyclical 
process, where alternating activation and repression takes place. 
 
 
2.2.3 1α,25(OH)2D3 analogs as VDR ligands 
 
It is well established that 1α,25(OH)2D3-activated VDR possesses many potential 
therapeutic features and is therefore a very interesting target for medical applications. 
However, several clinical trials with 1α,25(OH)2D3 have been failed because of the 
hypercalcemic toxicity of the hormone (Deeb et al., 2007). Therefore over 3000 
1α,25(OH)2D3 analogs have been designed over the years in order to prevent 
hypercalcemia and to improve biological capacity of the natural hormone in hyper-
proliferative diseases, such as cancer, or in bone disorders, such as osteoporosis (Bouillon 
et al., 1995; Carlberg & Mouriño, 2003). Most of the analogs carry a modification in their 
side chain, which in many cases also declines their 24-OHase-mediated degradation and 
increases stability of the VDR-ligand complex (van den Bemd et al., 1996; Bury et al., 
2001). In addition, many analogs have either low or sometimes extremely low affinity to 
DBP (Bouillon et al., 1996). Low DBP binding and altered intracellular metabolism of 
analogs compared to natural ligand creates also distinctive tissue-specific pharmacokinetic 
features for VDR ligands. 
 
Most of the 1α,25(OH)2D3 analogs are agonists and only few are identified as antagonists. 
An interesting analog is Gemini, which has two identical side chains (Figure 2) and has 
therefore a 20% bigger volume than natural ligand (Herdick et al., 2000; Norman et al., 
2000). Despite the size of Gemini, the LBP of the VDR is flexible enough to accommodate 
Gemini in two different conformations (Väisänen et al., 2003; Molnár et al., 2006). As one 
of the side chains takes the same position as that of natural ligand, Gemini acts as an 
agonist. In contrast, Gemini can act as an inverse agonist, when both side chains take 
alternative position to that of natural hormone (Gonzales et al., 2003). Further changes 
between agonistic and inverse agonistic conformations were found to response in cellular 
CoA and CoR levels. In normal or CoA-rich circumstances Gemini acts as an agonist and 
stabilizes VDR into active conformation, but at CoR excess Gemini can bind the LBP in 
inverse agonistic conformation, actively recruits CoRs to the VDR and induces repression. 
These features suggest that Gemini can sense the CoA/CoR ratio, which is an important 
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cell-specific characteristic. Taken together, 1α,25(OH)2D3 analogs have improved 
biological properties compared to that of the natural ligand without having hypercalcemic 
side effects and are therefore of great interest in research due to their potential for different 
type of therapeutic applications.  
 
  1α,25(OH)2D3   Gemini 
 
Figure 2. Molecular structure of 1α,25(OH)2D3 and Gemini. Gemini differs from 1α,25(OH)2D3 by 
having two identical side chain branching from carbon 20, while 1α,25(OH)2D3 has only one. 
 
 
2.3 Chromatin structure 
 
In every human cell there is almost 2 m of DNA-helix packed into the nucleus of about 10 
µm diameter. This can be achieved only by tight organization of DNA into a complex with 
histone-proteins to form nucleosomes (Figure 3). In one nucleosome 145-147 bp of DNA-
helix with a diameter of 2 nm is wrapped in 1.75 turns around a globular histone octamer 
to form a nucleosome core (Luger et al., 1997). Core nucleosomes are separated by 10 to 
90 bp of intervening linker-DNA. This forms chromatin structure that is considered as a 10 
nm fibre or “bead on a string” conformation and is about 5- to 10-fold condensed 
(Felsenfeld & Groudine, 2003). The histone octamer is built from two subunits of each 
histone proteins, H2A, H2B, H3 and H4, which consist of a C-terminal histone fold 
domain and N-terminal tail domain (Hansen, 2002; Horn & Peterson, 2002). Histone fold 
domains form the actual core of the nucleosome with histone-histone and histone-DNA 
interactions, while tail domains are point outside from core nucleosome and serve as sites 
for posttranslational modifications (Luger et al., 1997; Hansen, 2002; Horn & Peterson, 
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2002). In addition, histone tails are able to associate with linker-DNA or with adjacent 
nucleotides.  
 
 
Figure 3. Structure of multiple levels of chromatin condensation (Adapted from Horn & Peterson, 2002). 
Histone octamers and wrapped DNA-strand form core nucleosomes and 10 nm DNA fiber by 
internucleosomal interactions. Histone H1 stabilizes the next condensation level, 30 nm fiber, which can be 
further condensed by fibre-fibre interactions. 
 
Furthermore, the 10 nm fibre can be folded into a fibre with a diameter of about 30 nm 
producing a net compaction about 50-fold. This 30 nm fibre is stabilized by the linker-
protein, histone H1, which binds the core nucleosome and linker-DNA to condense the 
structure even more (Felsenfeld & Groudine, 2003). In further condensation, the 30 nm 
fibre is through long-range fibre-fibre interactions folded into higher order structures. 
There are several models how chromatin is packed in higher condensation rates, but 
detailed structures and compaction rates remain still unknown (Horn & Peterson, 2002). In 
addition, the diameter of higher compaction of chromatin folding is observed to vary from 
80 nm to several hundred nanometers (Horn & Peterson, 2002; Felsenfeld & Groudine, 
2003).  
 
Transcription requires group of enzymes, transcription factors and cofactors to either 
directly access into the chromatin or to the proteins associated with chromatin. Therefore 
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chromatin is static and highly packed only during the metaphase of mitosis, while 
interphase chromatin is very dynamic and in constant change between condensing and 
decondensing states (Wegel & Shaw, 2005). Chromatin is decondensed during gene 
activation and is condensed, when genes are silenced. When chromatin is decondensed, 
also referred as open chromatin, it is accessible for NRs and other components of the 
transcription machinery (Elgin & Grewal, 2003; Wegel & Shaw, 2005). In addition, gene-
rich areas of chromosomes are usually observed as very heterogeneous open chromatin, 
while repetitive units and gene-poor areas of chromatin, such as centromers and telomers, 
are usually condensed (closed chromatin) and not accessible for the transcription 
machinery. However, open chromatin does not always mean transcriptional activity and it 
has been shown that gene-rich open chromatin can also be transcriptionally inactive 
(Gilbert et al., 2004). In contrast, gene can be active in a gene-poor and largely condensed 
chromatin area, if there is enough local decondensation to open chromatin for transcription 
machinery. Therefore, it is suggested that open chromatin is required for transcription, but 
does not always stand for it. 
 
The central mechanisms for modifying higher order of chromatin folding are 
posttranslational modifications of amino acid residues of the histone tails, such as lysine 
acetylation, lysine or arginine methylation and serine phosphorylation (Spotswood & 
Turner, 2002). In addition, histones can be modified by adding small peptides, such as 
ubiquitin or ubiquitin-like proteins (Gill, 2004). These posttranslational modifications of 
histone tails are reversible and in every histone type there are several possible positions for 
different modifications. When put together, these modifications form a large complex of 
different combinations. In addition, within the genomic region of one gene there can be 
several hundreds of nucleosomes. Different combinations of modifications can efficiently 
affect chromatin condensation and transcriptional regulation in a combination-dependent 
manner and thus it is suggested that histone tail modification patterns can contain 
epigenetic information, called the histone code (Jenuwein & Allis, 2001; Turner, 2002). 
Furthermore, once chromatin is opened, the next level of chromatin modification can be 
achieved through ATP-dependent nucleosome remodelling that was first observed in vitro 
in Drosophila embryo extracts (Varga-Weisz et al., 1995). With nucleosome remodelling, 
accessibility of DNA is increased even more by stripping DNA from nucleosomes through 
energy-dependent relocation, reassembling and sliding of histone octamers (Becker, 2002).  
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2.3.1 Histone acetylation and deacetylation 
 
Probably the best understood type of histone modification is acetylation of the lysine 
residues in core histone tails, which is executed by enzymes with HAT activity. Generally, 
histone acetylation is connected to gene activity through local chromatin decondensation, 
while decreased acetylation levels are associated with transcriptional repression. 
Acetylation of histones neutralizes positive charges of lysine residues and decreases their 
affinity to DNA, which in turn increases accessibility of transcription factors to DNA 
(Grunstein, 1997). However, histone acetylation does not limit only to the regulation of 
transcription, since there is also group of HAT proteins that are located in cytoplasm and 
are acetylating newly synthesized histones to assemble them as already acetylated into 
chromatin (Brownell, 1996). In addition, removing of acetyl groups is mediated by 
HDACs, which mediate chromatin condensation. NRs can interact with HDACs via CoRs 
whereas many CoAs possess HAT activity (Castillo et al., 1999; Polly et al., 2000). 
Therefore, histone acetylation is general part of NR-mediated transcription. 
 
HDACs are a 18-member group of proteins consisting of two protein families with HDAC 
activity; the classic HDAC family (HDACs 1-11) and sirtuin family (SIRTs 1-7). These 
proteins can be further divided into four different classes (Table 1). HDACs do not bind 
directly to DNA and are usually part of a large multi-protein complex (Verdin et al., 2003). 
Class I HDACs are found almost exclusively in the nucleus, are ubiquitously expressed 
and seem to be involved in general cellular processes (Verdin et al., 2003; Gregoretti et al., 
2004). In addition, HDAC3 can stably associate with the CoRs SMRT and NCoR to form 
multi-protein repressor complex.  
 
In contrast to Class I, HDACs of Class II are able to shuttle between nucleus and 
cytoplasm in response to cellular signals and their mRNA expression is tissue specific. 
Class II can be further divided in two subgroups (IIa and IIb) based on their domain 
organization and sequence homology (Verdin et al., 2003). Furthermore, Class IIa HDACs 
4, 5 and 7, having rather low deacetylase activity, are able to mediate their deacetylation 
by association directly with SMRT/NCOR-complex, which is a part of a multi-protein 
complex containing HDAC3 (Fischle, 2001; 2002). Without HDAC3 this complex is 
inactive, which suggest that HDAC3 brings enzymatic activity to that stable complex, 
while HDAC4, 5 and 7 can regulate this complex by recruiting it to gene promoters.  
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HDAC11, that forms alone the Class IV, is found primarily in nucleus. It is evolutionally 
related to HDAC3 and HDAC8, but it is not found from any known HDAC complexes, 
which suggest that it has biochemically distinct function (de Rujiter et al., 2003). 
Furthermore, sirtuins, that form Class III, are related to the yeast Sir2 protein and are also 
found in multi-protein complexes. All sirtuins are NAD-dependent deacetylases, while all 
other HDACs, in contrast, require zinc ion as a substrate into charge-relay deacetylation 
activity. In general, HDACs are important mediators of deacetylation and act as 
components of diverse repressor complexes. 
 
Table 1. HDACs can be divided in four classes. HDACs 1, 2, 3 and 8 forms Class I. Class II can be divided 
in two subgroups, of which group a consists of HDACs 4, 5, 7 and 9, while HDACs 6 and 10 belong to group 
b. All 7 sirtuins form Class III and HDAC11 alone makes up Class IV. 
   Class I     HDAC1, HDAC2, HDAC3, HDAC8 
   Class IIa 
   Class IIb 
    HDAC4, HDAC5, HDAC7, HDAC9  
    HDAC6, HDAC10 
   Class III     SIRT1-7 
   Class IV     HDAC11 
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2.4 IGFBP3 
 
2.4.1 IGFBP3 as a modulator of IGF signaling 
 
IGFBPs are a family of proteins that regulate IGF-system by binding IGFs with high 
affinity. There are six well-identified mammalian IGFBPs, named IGFBP1 through 
IGFBP6, that are produced mainly by hepatic cells (Hwa et al., 1999; Zimmermann et al., 
2000). The IGF system is the mediator for cellular mitogenic signals; its role in cell growth 
and differentiation is well established. The system consists of circulating IGF-I and IGF-II, 
which mediate their growth signals in target tissues through cell surface receptors, type I 
and II IGF-receptors (IGF-IR and IGF-IIR) or insulin receptor. Both IGFs (IGF-I and IGF-
II) are mediating their mitotic signals mainly by binding and activating the IGF-IR (Hwa et 
al., 1999). Most of the IGFs are produced by hepatocytes in response to growth hormone 
stimulation and subsequently secreted to circulation to mediate mitogenic signals in target 
tissues (Zimmermann et al., 2000). 
 
In circulation, IGFs (sized about 7 kDa) are rapidly degraded with a half-life of roughly 10 
min (Baxter, 1994). To stabilize IGFs, over 90 % are bound to ternary complex, composed 
of one molecule of each IGF, acid-labile subunit (ALS) and IGFBP3, with total size of 150 
kDa. In the complex, IGF’s half-life is found to increase up to 15 h (Guler et al., 1989). 
Interestingly, IGFBPs bind to IGFs with higher affinity than IGFs bind to their receptors 
and therefore IGFBP3, as a main binder of IGFs, is not only carrier and stabilizer of IGFs 
but is also able to regulate its bioavailability and signaling through IGF-Rs (Hwa et al., 
1999). Moreover, a study performed with promyeloid HL-60 and monocytic U-937 cell 
lines has shown that IGFBP3 is able to suppress IGF-induced proliferation in these cells, 
while des-(1-3)-IGF-I, an IGF-I analog that does not bind to IGFBP3, stimulated cell 
proliferation (Li et al., 1997). In addition, membrane-associated IGFBP3 attenuates IGF-I-
induced IGF-IR signaling in endometrial cancer cells overexpressing both IGF-IR and 
membrane-bound IGFBP3, while des-(1-3)-IGF-I caused receptor activation (Karas et al., 
1997). In contrast, the same study showed that fibroblast cells lacking membrane-bound 
IGFBP3 but overexpressing IGF-IR showed similar IGF-IR activation to IGF-I and des-(1-
3)-IGF-I. These findings establish that IGFBP3 has significant growth-inhibitory effects by 
preventing IGF-I binding to IGF-Rs. 
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Most of the circulating IGFBP3 is produced by hepatic Kupffer cells and endothelial cells 
to assemble them into the IGF-ALS-IGFBP3 complex or to secrete to circulation. 
However, IGFBP3 is produced also in a tissue-specific manner to mediate auto- and 
paracrine growth regulation (Yamada & Lee, 2009). In addition, IGFBP3 expression is 
found to be inducible by several growth inhibition agents, such as 1α,25(OH)2D3, 
transforming growth factor-β (TGF-β), TNF-α and retinoic acid in various cancer cell 
types, such as breast, prostate and fibroblast cancer cells. The IGFBP3 gene is a primary 
1α,25(OH)2D3 target and has three response elements in its promoter (Figure 5, page 37), 
of which first two are located as tandem at position -400 bp (RE1/2) and third at position -
3350 bp (RE3) (Matilainen et al., 2005). Rat prostate in vivo and prostate cancer in vitro 
studies with 1α,25(OH)2D3 and its analogs have shown that ligand treatment induces 
IGFBP3 expression, which leads to decreased cell proliferation (Nickerson & Huynh, 
1999). This locally induced IGFBP3 is suggested to decrease IGFs availability and hence 
inhibit prostate or cell growth. Growth inhibition of MCF-7 and Hs578T human breast 
cancer cells induced by 1α,25(OH)2D3 was also associated with increased IGFBP3 
expression (Colston et al., 1998). Furthermore, during p53-mediated apoptosis of colon 
carcinoma cells, p53 was directly found to up-regulate IGFBP3 expression via two p53 
response elements found in IGFBP3 introns (Buckbinder et al., 1995).  
 
 
2.4.2 IGF-independent actions of IGFBP3 
 
Circulating or locally produced IGFBP3 is also able to mediate IGF-independent growth 
inhibition signaling. In addition, induction of IGFBP3 expression is a central tool studying 
IGF-independent actions in different cell types. It is suggested that IGFBP3 mediates its 
growth signaling actions through specific cell surface receptor, but to date, the specific 
receptor has not been published (Yamada & Lee, 2009). There are two putative receptors; 
firstly, Leal et al. (1997) found that in mink lung epithelial cells IGFBP3 binds to TGF-β 
type V receptor, but detailed signaling mechanism remains unknown. Secondly, Yamanaka 
et al. (1999) found that IGFBP3 to binds unknown receptor in breast cancer cell surface. 
Signaling of the receptor remains unknown, but it was found to bind IGFBP3 with high 
affinity and specificity. In addition, IGFBP3 contains a nuclear localization signal in its 
sequence and it has been shown to localize in nucleus (Jacques et al., 1997; Schedlich et 
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al., 1998). In the nucleus, IGFBP3 is able to directly control transcription by binding to 
RXRα (Liu et al., 2000). RXRα is also required for IGFBP3-mediated apoptosis. 
Furthermore, it has been shown that IGFBP3 stimulates RXR-α-Nur77-heterodimers to 
translocate from the nucleus into mitochondria, which initiates caspase activation and 
apoptosis (Lee et al., 2005). 
 
However, IGFBP3 is able to mediate its growth inhibitive actions without binding to the 
cell surface or localizing into the nucleus. Increased IGFBP3 expression was shown to lead 
caspase-mediated apoptosis with reduced IGFBP3 cell surface binding and without 
localization into nucleus in study performed with T47D breast cancer cells (Butt et al., 
2002). In LNCaP prostate cancer cells IGFBP3 induced by 1α,25(OH)2D3 was found to be 
critical for induction of CDKN1A expression and growth inhibition mediated by its gene 
product, p21 (Boyle et al., 2001). When IGFBP3 was withdrawn, no growth inhibition or 
CDKN1A expression was observed in response to 1α,25(OH)2D3. In contrast, a previous 
prostate cancer study (Nickerson & Huynh, 1999) suggested that 1α,25(OH)2D3 and its 
analogs induce IGFBP3-mediated but IGF-dependent growth inhibition. These findings 
establish that there are several pathways for IGFBP3 to inhibit cell growth and these 
pathways may be also cell-type specific. 
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3 AIMS OF THE STUDY 
 
This study aims to investigate VDR-mediated regulation of the IGFBP3 gene by using two 
different VDR ligands; 1α,25(OH)2D3 and Gemini. More specific aims are: 
 
1. To study the effects of 1α,25(OH)2D3 and Gemini treatment on IGFBP3 mRNA 
accumulation in MCF-10A cells by using real-time quantitative (RT-q) PCR. 
 
2. To monitor the ligand-mediated changes in VDR binding and histone 4 acetylation level 
at VDREs in IGFBP3 promoter by using ChIP assays. 
 
3. To study the role of HDACs in IGFBP3 mRNA accumulation induced by VDR ligands. 
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4 MATERIALS AND METHODS 
 
4.1 Cell culture 
 
All experiments in this thesis were done with MCF-10A cells. The human mammary 
epithelial cell line MCF-10A is an estrogen receptor negative and non-tumorigenic 
immortalized cell line. MCF-10A were grown in a mixture of phenol red-free Dulbecco’s 
modified Eagle’s medium (DMEM) and Ham’s F12 medium (1:1) with 20 ng/ml of 
epidermal growth factor, 100 ng/ml of cholera toxin, 10 µg/ml insulin, 500 ng/ml 
hydrocortisone, 0.1 mg/ml streptomycin, 100 U/ml penicillin and 5% horse serum. Cells 
were grown in humidified 95% air / 5% CO2 incubator at 37 °C.   
 
For mRNA and ChIP experiments the cells were seeded in the above-mentioned medium 
but with 5% charcoal-stripped fetal bovine serum (FBS) instead of horse serum. FBS was 
stripped of lipophilic compounds by stirring it with 5% (w/v) activated charcoal (Sigma-
Aldrich) for 3 h at room temperature. Charcoal was then removed by centrifugation and 
sterile filtration (0.2 mm pore size). The cells were grown for 24 h to reach a density of 50 
to 60% confluence. 
 
During experiments, the cells were treated with either EtOH (0.001%), 1α,25(OH)2D3 or 
Gemini (both ligands were kindly provided by Dr. Milan Uskokovic, BioXell Inc., Nutley, 
NJ, USA). 1α,25(OH)2D3 and Gemini were used at a final concentration of 10 nM diluted 
in DMEM with 0.001% EtOH. All treatments were done without refreshing the medium. 
 
 
4.2 RNA extraction and cDNA synthesis  
 
Cells were seeded into 6-well plates and grown 24 h before ligand treatment. The cells 
were stimulated with ligands for indicated time periods. Total RNA was isolated from the 
cells using High Pure RNA Isolation Kit (Roche Diagnostic, Mannheim, Germany) as 
instructed by the manufacturer. Lysis of the cells was performed by adding 200 µl 
phosphate buffered saline (PBS; 150 mM NaCl, 2 mM KCl, 1.5 mM KH2PO4, 10 mM 
Na2HPO4 x H2O) and 400 µl lysis buffer directly on culture plate after washing cells once 
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with PBS. Final elution of RNA was done in 50 µl of elution buffer. Total RNA amount 
and purity was quantified with a NanoDrop ND-1000 spectrophotometer (NanoDrop, 
Wilmington, DE, USA) 
 
cDNA synthesis was performed using the Transcriptor First Strand cDNA synthesis kit 
(Roche, Mannheim, Germany) as instructed by the manufacturer. Template RNA (1 µg) 
was pre-incubated for 10 min with 50 pmol oligo(dT)18 primer at 65 °C to denature 
secondary structures of RNA. Oligo(dT)18 primers anneal to poly-A tail of mRNA. The 
synthesis was performed for 30 min at 55 °C in a total volume of 20 µl. After synthesis, the 
reaction was stopped by incubation for 5 min at to 85 °C; reaction mix was diluted then to 
a final volume of 400 µl with sterile H2O. 
 
 
4.3 siRNA inhibition 
 
For knockdown mRNA expression, cells were reverse-transfected with small inhibitory 
RNA (siRNA, oligonucletides shown in Table 2) using Lipofectamine RNAiMAX reagent 
(Invitrogen, Carlsbad, CA, USA). The positive surface charge of the liposome formed by 
reagent interacts with the siRNA oligonucleotides, allowing them to enter the cell through 
the negatively charged cell membrane. Three specific double-stranded oligos against a 
particular gene were used simultaneously and single unspecific control oligonucleotide 
was used as a control. Control transfection was always performed for same time points as 
for siRNA-transfection. First, the siRNA oligonucleotides (Eurogentec, 200 pmol of each 
or 600 pmol of control) were diluted to 500 µl of cell culture medium, but without 
antibiotics and serum. Then 5 µl RNAiMAX reagent was added and the mixture was 
incubated for 15-20 min at room temperature and laid to 6-well plates. MCF-10A cells 
(350,000) were added in 2.5 ml of medium with serum into the wells. The transfection was 
continued for 24 h before ligand treatment. RNA extraction and cDNA synthesis of treated 
cells were done as described previously. Transfection efficiency was monitored by 
measuring mRNA expression of the silenced gene from both control and siRNA samples 
with RT-qPCR and Western blot analysis. 
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Table 2. siRNA oligonucleotides. Location (relative to the TSS) and sequence of siRNA oligonucleotides 
used for gene-specific knockdown.  
Target gene Location  Sequence of + oligonucleotide (5’ - 3’) 
Control - UGCGCUACGAUCGACGAUG 
HDAC4 1117 
1521 
3279 
CGAGCACAUCAAGCAACAA 
CAGCUUCUGAACCGAAUCU 
GCGUGAGCAAGAUCCUCAU 
HDAC6 174 
1771 
2621 
GUGUCACUUCGAAGCGAAA 
CCGUGAGAGUUCCAACUUU 
GGACCCUCCAGUUCUAAGU 
 
 
4.4 PCR-primer design 
 
RT-qPCR primers were designed with Oligo 4.0-s-software (National Biosciences, 
Plymouth, MN, USA). Primers for mRNA quantification (Table 3) were designed in a 
manner that either another primer overlaps with two exons, or there exists a large (several 
thousand base pairs) intron between primers to prevent possible replication of genomic 
DNA contamination in cDNA samples. Other primers were designed to achieve annealing 
energy of primer itself or between primer pair to be as near to zero as possible. Acceptable 
dimerization energy was between 0 and -5 kcal/mol. If possible, primers were designed to 
end with a C or a G at 3’ end. PCR-product length was between 80 and 150 bp and no 
hairpin formation was accepted. Specificity of designed primers was determined with 
nucleotide-BLAST searches from human genome or transcriptome database maintained by 
National Center for Biotechnology Information (NCBI). A criterion for specificity was that 
primer sequence is unique for DNA or cDNA sequence of interest and no exception were 
accepted. The designed primers were produced by Oligomer (Oligomer, Helsinki, Finland) 
 
The PCR conditions for the designed primers were optimized with RT-qPCR machines 
(My-IQ-cycler, BioRad, California, USA) using Maxima™ SYBR Green/Fluorescein 
qPCR Master Mix 2 × (Fermentas, Vilnius, Lithuania). The reaction was performed with 8 
µl of cDNA template and 4 pmol of both forward and reverse primers in total volume of 20 
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µl. The PCR cycling conditions used were 10 min at 95 °C, 45 cycles for 30 s at 95 °C, for 
30 s at 56-66 °C and for 30 s at 72 °C, followed by further elongation for 10 min at 72 °C 
and melting curve analysis. The primer-specific annealing temperature was determined 
from Ct-values, melting curve and agarose gel electrophoresis results (Table 3). 
 
Table 3. RT-qPCR primers. Sequences, product sizes and annealing temperatures of primer pairs used for 
gene-specific RT-qPCR.  
Gene Primer pairs (5’ - 3’) Product 
size (bp) 
Annealing 
temperature (°C) 
RPLP0 AGATGCAGCAGATCCGCAT 
GTGGTGATACCTAAAGCCTG 
318 58-62 
IGFBP3 AAGTTGACTACGAGTCTCAG  
ACGGCAGGGACCATATTC 
83 58 
HDAC1 GATCTGCTCCTCTGACAAAC 
GACTTCTTTCTTCTCCTCTG 
159 60 
HDAC2 CAGTGGAGATGAAGATGGAG 
TTTCACCACTGTTGTCCTTG 
241 60 
HDAC3 CTTCATCCAGATGTCAGCAC 
TCCACATCGCTTTCCTTGTC 
268 60 
HDAC4 GCATGTGTTTCTGCCTTGCTG 
GTTCTCGCAAGTCTGAGCCT 
191 60 
HDAC5 ATGCTGTTGAAGGACATCTG 
TCTGGATCTCGATGACTTTC 
272 60 
HDAC6 GCAAGGGATGGATCTGAACC 
CTAGGCTGTGAACCAACATC 
201 60 
HDAC7 CTCACTGTCAGCCCCAGAG 
TGTCACGCAGGACCACTG 
249 62 
HDAC8 ACCAGATCTGTGAAAGTGTAC 
AACTAGACCACATGCTTCAG 
414 60 
HDAC9 GCAGATCCACATGAACAAACTG 
GATCTGAGCATCTTCATCACTG 
240 60 
HDAC10 ATTGAAAGAACAAATGCG 
CTCTGGGCTCCGTGGGAC 
367 62 
HDAC11 GGACGACAAGCGTGTGTACATC 
AGCGGTGTGTCTGAGTTCTGTG 
443 60 
 
 31 
4.5 RT-qPCR 
 
RT-qPCR was performed with a LightCycler® 480 System (Roche Diagnostic, Mannheim, 
Germany) using Maxima™ SYBR Green/ Fluorescein qPCR Master Mix 2 × (Fermentas). 
The reaction was performed with 4 µl of cDNA template and 4 pmol of both forward and 
reverse primers in a total volume of 10 µl. All primer sequences and primer-specific 
annealing temperatures are presented in Table 3. In the PCR, DNA was pre-denaturated for 
10 min at 95 °C, followed amplification steps cycles (45 cycles) of 20 s denaturation at 95 
°C, 20 s annealing at primer-specific temperature and 20 s elongation at 72 °C, followed 
by further elongation for 10 min at 72 °C and melting curve analysis. 
 
Fold inductions were calculated using the formula 2-(ΔΔCt), where ΔΔCt is ΔCt(stimulus) - 
ΔCt(solvent), ΔCt is Ct(target gene) - Ct(contol gene). Control gene used was housekeeping gene 
ribosomal protein, large, p0 (RPLP0). Quality of the PCR product was monitored using 
post-PCR melt curve analysis. All PCR reactions were done as triplicates and two-tailed 
Student's t-tests were performed to determinate p-values in reference to non-treated cells to 
treatments. 
 
 
4.6 ChIP assay 
 
ChIP was used to determine certain protein binding or histone acetylation level on VDREs 
on the IGFBP3 promoter. The cells were seeded into 175 m2 cell culture bottles with 20 ml 
medium and grown for 24 h. Before treatments volume of medium was reduced to 10 ml. 
The cells were stimulated with 1α,25(OH)2D3 or Gemini for indicated time points and 
nuclear proteins were cross-linked to chromatin by adding formaldehyde directly to the 
medium to a final concentration of 1%. After 5 min cross-linking at room temperature 
reaction was stopped by adding glycine (final concentration 0.125 M) and incubating for 5 
min at room temperature on rocking platform. Cells were washed twice with ice-cold PBS, 
scraped into 5 ml PBS and moved to 15 ml tube. To ensure that all cells are transferred to 
the tube, cell culture bottle was washed twice with 5 ml PBS and washing solution was 
transferred to the tube. Cells were pelleted by centrifugation (700 × g for 5 min at 4 °C) 
and the pellet was resuspended in 600 µl of lysis buffer [1% SDS, 10 mM EDTA, 50 mM 
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Tris-HCl, 1 × protease inhibitor cocktail (Complete, Roche Diagnostic, Mannheim, 
Germany), pH 8.1] for 10 min at room temperature in 1.5 ml tubes. The lysate was 
sonicated 10 min by Bioruptor UCD-200 (Diagenode, Liege, Belgium) with intervals of 20 
s sonication and 40 s hold in between to result in the majority of DNA fragments being 
300-1000 bp in length. Cellular debris was removed by centrifugation for 10-15 min at 4 
°C with 16000 × g. For the input samples, 50 µl of the lysate was diluted 1:10 in ChIP 
dilution buffer (0.01% SDS, 1.1% Triton-X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM 
Tris-HCl, pH 8.1), stored at 4 °C and further processed as the outputs from step reverse-
crosslinking. The remaining lysate was aliquoted to 100 µl aliquots (output samples) and 
diluted 1:10 in ChIP dilution buffer enriched with 1 × protease inhibitor cocktail and 250 
µg/ml of BSA. The output samples were incubated with respective antibodies (Table 4) for 
overnight at 4 °C on a rocking platform to form immuno-complexes. 
 
The immuno-complexes were collected with 60 µl of protein A agarose slurry (Millipore, 
Temecula, CA, USA) for 1 h at 4 °C with rotation. EtOH of protein A agarose was 
changed to ChIP dilution buffer before using it. The beads were pelleted by centrifugation 
for 1 min at room temperature at 100 × g and washed sequentially 3 min by rotation with 1 
ml of the following buffers: low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl and 20 mM Tris-HCl, pH 8.1), high salt wash buffer (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 500 mM NaCl and 20 mM Tris-HCl, pH 8.1) and LiCl 
wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA 
and 10 mM Tris-HCl, pH 8.1). Finally, the beads were washed twice with 1 ml TE buffer 
(1 mM EDTA and 10 mM Tris-HCl, pH 8.0). After each step beads were pelleted by 
centrifugation (100 × g for 1 min at room temperature) and the supernatant was aspirated. 
Immuno-complexes were eluated with 500 µl elution buffer (25 mM Tris-HCl, pH 7.5, 10 
mM EDTA, 0.5% SDS) for 30 min at 65 °C. 
 
Remaining proteins were digested from both output and input samples by adding 
proteinase K (final concentration 80 µg/ml, Fermentas) and simultaneously reverse cross-
linked by incubating overnight at 64 °C. The DNA was recovered by 
phenol/chloroform/isoamyl alcohol (25:24:1, 500 µl per sample) extraction. After 
centrifugation (14,000 × g for 5 min at room temperature) the supernatant was transferred 
to fresh tube and DNA was precipitated with 50 µl of 3 M sodium acetate (pH 5.2) and 1 
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ml of ice-cold EtOH using 1.5 µl glycogen as a carrier (20 mg/ml, Fermentas). The DNA 
was pelleted with centrifugation (14,000 × g for 20 min at 4 °C) and the pellet was washed 
with 700 µl ice-cold 70% EtOH. Air-dried input and output samples were dissolved in 100 
µl and 50 µl of H2O, respectively. The difference in final volumes and the difference in the 
amount of starting material used were taken into account when calculating the PCR results. 
 
Table 4. Antibodies used in chromatin immunoprecipitation.  
Antibody target Code Amount used Supplier 
IgG 12-370, 1 mg/ml 1 µl per sample Upstate 
VDR SC-1008, 200 µg/ml 5 µl per sample Santa Cruz 
AcH4 06-866, 1 mg/ml 1 µl per sample Upstate 
HDAC4 SC-11418 5 µl per sample Santa Cruz 
HDAC6 SC-11420 5 µl per sample Santa Cruz 
 
 
4.6.1 RT-qPCR of chromatin templates  
 
Two primer pairs were designed to cover two VDREs regions within the IGFBP3 promoter 
(Table 5). Quantification of the RT-qPCR products was done using specific TaqMan 
probes labeled with 6-carboxyfluorescein (FAM) (Eurogentec, Liege, Belgium) (Table 6). 
The use of these probes ensures that only the particular PCR product of interest is 
quantified, because unique probe-sequence is complementary to the sequence of PCR 
product and therefore is targeting only the product of interest. 
 
RT-qPCR was performed with LightCycler® 480 System (Roche Diagnostic, Mannheim, 
Germany) using Maxima Probe qPCR master mix 2 × (Fermentas, Vilnius, Lithuania). The 
reaction was performed with 3 µl of ChIP template and 4 pmol of both forward and reverse 
primers and 0.25 pmol TaqMan probe in a total volume of 10 µl. In the PCR, DNA was 
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pre-denaturated for 10 min at 95 °C, followed 2-step amplification steps cycles (50 cycles) 
of 20 s denaturation at 95 °C and 60 s annealing and elongation at 60 °C with all primers. 
 
Relative association of the chromatin bound proteins or histone acetylation level were 
calculated using the formula [2-(ΔCp)*100% specific antibody - 2-(ΔCp)*100% non-specific 
IgG], where ΔCt is the Ct(output)-Ct(input) and Ct is the cycle, where the threshold is crossed 
and normalized by the amount of chromatin used for preparation of input versus output. 
All PCR reactions were done as triplicates and two-tailed Student's t-tests were performed 
to determinate P-values in reference to non-treated cells to treatments. 
 
Table 5. ChIP primers. Location (relative to TSS) and sequences of the PCR primer pairs used to detect two 
genomic regions on IGFBP3 promoter. 
Region Location Primer sequence (5’ - 3’) 
RE1/2 - 419 to - 293 
CGCTGTATGCCAGTTTCC 
TCACCCCAGTCACTCCTG 
RE3 - 3401 to - 3256 
CTCCCACATTGTTTAAGACTC 
GTAGGCAGTGTGACAGCAG 
 
 
Table 6. Sequences of FAM-modified qPCR probes. These probes carry at their 5’ end a FAM group and 
were used for the quantification of ChIP products. 
Probe target Location Primer sequence (5’ - 3’) 
RE1/2 -389 to -369 TCGCCGCAGGGAGACCTCAC 
RE3 -3376 to -3351 TCAAATGCCACCACCTCTCAGAAGT 
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5 RESULTS 
 
5.1 Cyclical induction of IGFBP3 mRNA expression by 1α ,25(OH)2D3   
 
MCF-10A cells were treated with 10 nM 1α,25(OH)2D3 or Gemini in a detailed time 
course of 240 min with 15 min intervals. RT-qPCR was performed in order to monitor 
VDR-mediated mRNA induction profile of IGFBP3 in response to these two VDR ligands. 
In response to 1α,25(OH)2D3 mRNA induction found to be cyclical and showed peaks after 
90, 150 and 210 min, which shows a periodicity of 60 min (Figure 4A). After each peak 
mRNA level was decreased. In response to Gemini, induction was linear increasing 
continuously (Figure 4B). Induction of mRNA was also far more stronger in response to 
Gemini (5.5-fold induction at 240 min) than to 1α,25(OH)2D3 (2.6-fold induction maxima 
at 210 min). Taken together, in response to 1α,25(OH)2D3 mRNA induction of IGFBP3 
takes place only in 60 min pulses while in response to Gemini mRNA expression is 
continuously active. The basal level of IGFBP3 mRNA expression is shown in Figure 12. 
 
 
5.2 VDR binding to the IGFBP3 promoter in response to 1α ,25(OH)2D3 
and Gemini 
 
To study, whether the cyclical changes in IGFBP3 mRNA expression in response to 
1α,25(OH)2D3 is based on VDR binding on the IGFBP3 promoter, ChIP assay was 
performed in 1α,25(OH)2D3 and Gemini treated cells with antibody against VDR (Figure 
5). ChIP assay was performed over a time period of 150 min. RT-qPCR using TaqMan 
probes was performed with chromatin templates to determine VDR binding on the two 
VDREs, RE1/2 and RE3 (Figure 5), located within IGFBP3 promoter.  
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Figure 4. Periodic changes in IGFBP3 mRNA expression. RT-qPCR was performed to determine the 
mRNA accumulation of the IGFBP3 gene in MCF-10A cells after treatment with 10 nM 1α,25(OH)2D3 (A) 
or Gemini (B) over a time period of 240 min with 15 min intervals. Data points indicate the means of at least 
three independent experiments and the bars represent standard deviations. A two-tailed Student’s t-test was 
performed to determine the significance of the mRNA induction in reference to solvent control and in 
comparison of the peaks to the minima (*p < 0.05, **p < 0.01, ***p < 0.001). 
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In response to 1α,25(OH)2D3 treatment, binding of VDR was cyclical and showed peaks at 
30 and 105 min in both VDRE regions (Figure 5A and C). After Gemini treatment VDR 
did not showed any cyclical association on RE1/2 (Figure 5B). In addition, no significant 
increase in VDR binding compared to time point 0 was observed. Gemini increased VDR 
binding on RE3 in cyclical fashion showing maximal levels at 45 and 120 min (Figure 
5D). 
 
 
 
Figure 5. Dynamic association of VDR with RE1/2 (A and B) and RE3 (B and D) on the IGFBP3 
promoter. ChIP assay using anti-VDR antibodies was performed on chromatin extracts from MCF-10A cells 
treated for indicated time points with 10 nM 1α,25(OH)2D3 (A and C) or Gemini (B and D). Data points 
indicate the means of at least three independent experiments and the bars represent standard deviations. A 
two-tailed Student’s t-test was performed to determine the significance of the time-dependent association of 
VDR in reference to time point 0 and in comparison of the peaks to the minima (*p < 0.05, **p < 0.01, ***p 
< 0.001). 
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5.3 Chromatin acetylation in response to 1α ,25(OH)2D3 and Gemini  
 
To study general chromatin activation of both VDREs within the IGFBP3 promoter, ChIP 
assay with antibodies against acetylated histone 4 (AcH4) was performed in MCF-10A 
cells that were treated for 30, 60, 90, 120 and 150 min with 1α,25(OH)2D3 or Gemini 
(Figure 6). On RE1/2 acetylation level of histone 4 stayed induced at 60 min in response to 
1α,25(OH)2D3 peaking at 90 min (Figure 6A). In contrast, Gemini treatment caused 
increased, but relatively stable chromatin acetylation compared to that with 1α,25(OH)2D3. 
With Gemini treatment acetylation level increased already at 30 min and stayed induced 
over the whole time period of 150 min. Gemini induced relatively high and stable 
acetylation level on RE3, while 1α,25(OH)2D3-mediated acetylation was also overall high, 
but at time points 30 min and 150 min significantly lower than Gemini. In general, 
acetylation levels of histone 4 in both VDREs were much more complex with 
1α,25(OH)2D3 than with Gemini. 
 
 
 
Figure 6. Acetylation level of histone 4 proteins in RE1/2 (A) RE3 (B). ChIP assay using anti-AcH4 
antibodies was performed on chromatin extracts from MCF-10A cells treated for indicated time points with 
10 nM 1α,25(OH)2D3 or Gemini. Data points indicate the means of at least three independent experiments 
and the bars represent standard deviations. A two-tailed Student’s t-test was performed to determine the 
significance of the time-dependent acetylation in reference to time point 0 and in comparison of the peaks to 
the minima (*p < 0.05, **p < 0.01, ***p < 0.001). 
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5.4 HDACs mRNA expression in response to 1α ,25(OH)2D3 and Gemini 
 
Gene expression of every of the 11 HDAC genes were studied with RT-qPCR in order to 
determine if they are primary 1α,25(OH)2D3 or Gemini targets. HDAC9 was not 
sufficiently expressed in MCF-10A cell-line to reliably measure with RT-qPCR (Figure 
12). Cells, that were treated over a time period of 240 min with 15 min intervals, showed 
that mRNA expression of only HDAC4 and HDAC6 found to be regulated by 
1α,25(OH)2D3 (Figure 7A and C), while other HDACs were not significantly regulated by 
1α,25(OH)2D3 (Figure 8). In response to 1α,25(OH)2D3 treatment, HDAC4 was regulated 
in a cyclical fashion with peaks at 30, 75, 150 and 210 min (Figure 7A), while HDAC6 
showed peaks only at 30 and 75 min. On the contrary, after Gemini treatment was found 
that neither HDAC4 nor HDAC6 was regulated by Gemini (Figure 7B and C). In addition, 
any of the other HDACs were directly regulated by Gemini (Figure 9). 
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Figure 7. HDAC4 and HDAC6 mRNA expression after VDR-ligand treatment. RT-qPCR was performed 
to determine the mRNA accumulation of the genes HDAC4 (A and B) and HDAC6 (C and D) in MCF-10A 
cells after treatment with 10 nM 1α,25(OH)2D3 (A and C) or Gemini (B and D) over a time period of 240 min 
with 15 min intervals. Data points indicate the means of at least three independent experiments and the bars 
represent standard deviations. A two-tailed Student’s t-test was performed to determine the significance of 
the mRNA induction in reference to solvent control and in comparison of the peaks to the minima (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
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Figure 8. mRNA expression of HDAC genes in response to 10 nM 1α,25(OH)2D3. RT-qPCR was 
performed to determine the mRNA accumulation of the genes HDAC1, 2, 3, 5, 7, 8, 10 and 11. in MCF-10A 
cells after treatment with 10 nM 1α,25(OH)2D3 over a time period of 240 min with 15 min intervals. Data 
points indicate the means of at least three independent experiments and the bars represent standard 
deviations. A two-tailed Student’s t-test was performed to determine the significance of the mRNA induction 
in reference to solvent control and in comparison of the peaks to the minima (*p < 0.05, **p < 0.01, ***p < 
0.001). 
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Figure 9. mRNA expression of HDAC genes in response to 10 nM Gemini. RT-qPCR was performed to 
determine the mRNA accumulation of the genes HDAC1, 2, 3, 5, 7, 8, 10 and 11. in MCF-10A cells after 
treatment with 10 nM Gemini over a time period of 240 min with 15 min intervals. Data points indicate the 
means of at least three independent experiments and the bars represent standard deviations. A two-tailed 
Student’s t-test was performed to determine the significance of the mRNA induction in reference to solvent 
control and in comparison of the peaks to the minima (*p < 0.05, **p < 0.01, ***p < 0.001). 
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5.5 Silencing of HDAC4 and HDAC6 mRNA expression by siRNA 
 
HDAC4 and HDAC6 genes were silenced simultaneously in MCF-10A cells by gene-
specific siRNA oligonucleotides. 24 h after transfection cells were treated with 
1α,25(OH)2D3 over a time period of 120 to 240 min. With control transfection 
1α,25(OH)2D3 treatment caused cyclical IGFBP3 mRNA accumulation showing peaks at 
135 and 210 min (Figure 10A). This result corresponds to results from non-transfected 
cells (Figure 10A). Interestingly, silencing of HDAC4 and HDAC6 abolished mRNA 
cycling of IGFBP3 caused by 1α,25(OH)2D3 and changes expression to linear (Figure 
10C). In contrast, IGFBP3 mRNA response to Gemini did not change after silencing 
HDAC4 and HDAC6 (Figure 10D) and expression profile was similar to that with control 
transfection (Figure 10B) or non-transfected cells (Figure 4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Effect of HDAC4 and HDAC6 silencing on the IGFBP3 mRNA expression. MCF-10A cells 
were transfected for 24 h with siRNA oligonucleotides against the HDAC4 and HDAC6 genes (C and D) or 
with a non-targeted control siRNA (A and B), and subsequently stimulated for indicated time points with 10 
nM 1α,25(OH)2D3 (A and C) or Gemini (B and D). RT-qPCR was performed to determine the mRNA 
accumulation of IGFBP3 of indicated siRNA. Data points indicate the means of at least three independent 
experiments and the bars represent standard deviations. A two-tailed Student’s t-test was performed to 
determine the significance of the mRNA induction in reference to solvent control and in comparison of the 
peaks to the minima (*p < 0.05, **p < 0.01, ***p < 0.001). 
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5.6 HDAC4 and HDAC6 association with VDREs on IGFBP3 promoter 
 
ChIP assay with antibodies against HDAC4 and HDAC6 was performed in cells that were 
treated over a time period of 150 min with 1α,25(OH)2D3 or Gemini (Figure 11). At region 
RE1/2 high basal association with HDAC4 was observed (Figure 11A). In response to 
1α,25(OH)2D3, association found to be cyclical and reduced to minima within 30 min, 
returned at 60 min and reduced again at 90 min. At region RE3 basal association of 
HDAC4 was not as strong as at RE3 (Figure 11C). After 1α,25(OH)2D3 treatment HDAC4 
association also reduced to minima at 45 min and slowly increased to normal at 135 min. 
In response to Gemini, association of HDAC4 reduced within 15 to 45 min on both VDRE 
regions (Figures 11B and 11D). HDAC4 association was restored at 60 min on both 
VDREs and stayed high on RE3 and, but decreased again on RE1/2 at time points 120 and 
150 min.  
 
In response to 1α,25(OH)2D3, basal association of HDAC6 reduced at time points 15, 60 
and 120 min on RE1/2 (Figure 11E) and at time point 15 min and over a time period of 60 
to 120 min on RE3 (Figure 11G). In response to Gemini, HDAC6 association reduced on 
RE1/2 after 15 min, increased above the basal at 60 and 75 min, reduced to basal at 90 to 
120 min, peaked at 135 min and was low at time point 150 min (Figure 11F). After Gemini 
treatment, HDAC6 association was reduced also on RE3 after 15 min, but stayed low over 
a time period to 45 min and 105 to 120 min (Figure 11H). In addition, HDAC6 levels were 
fully restored at time points 60 to 90 min and 135 to 150 min. 
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Figure 11. Association of HDAC4 and HDAC6 with RE1/2 and RE3 on the IGFBP3 promoter. ChIP 
assay using anti-HDAC4 (A, B, C and D) and anti-HDAC6 (E, F, G and H) antibodies was performed on 
chromatin extracts from MCF-10A cells treated for indicated time points with 10 nM 1α,25(OH)2D3 (A, C, E 
and G) or Gemini (B, D, F and H). Data points indicate the means of at least three independent experiments 
and the bars represent standard deviations. A two-tailed Student’s t-test was performed to determine the 
significance of the time-dependent association of HDAC4 or HDAC6 in reference to time point 0 and in 
comparison of the peaks to the minima (*p < 0.05, **p < 0.01, ***p < 0.001). 
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Figure 12. Basal mRNA expression of HDAC genes in MCF-10A cells. RT-qPCR was performed to 
determine the basal mRNA expressions of IGFBP3 and the 11 HDAC genes in relation to the housekeeping 
gene RPLP0 in untreated cells. Data points indicate the means of at least three independent experiments and 
the bars represent standard deviations. 
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6 DISCUSSION 
 
In this thesis, IGFBP3 mRNA accumulation was found to be inducible in a different 
fashion comparing the natural VDR ligand, 1α,25(OH)2D3, and the synthetic analog 
Gemini. The IGFBP3 gene is coding for a well-known growth regulator, is a primary VDR 
target and of high interest for studying 1α,25(OH)2D3-mediated growth inhibition in cancer 
cells. Therefore, it is also a good model for studying the molecular mechanisms of VDR-
meditated transcription. In this study, it was found that in response to 1α,25(OH)2D3, 
IGFBP3 mRNA accumulation was cyclical resulting in states of transcriptional activation 
and repression with a periodicity of 60 min, while the Gemini-induced mRNA 
accumulation was linear and more stable. Cyclical mRNA expression, mediated by 
1α,25(OH)2D3, led also to reduced total IGFBP3 induction (2.6-fold), compared to Gemini 
that showed a 5.5-fold maximal induction at time point 240 min.  
 
Ligand treatment affects gene regulation by activating NR-mediated gene expression. This 
response is initiated by ligand binding to NRs, which in turn leads to activation of the 
receptor and subsequently to transcription. However, transcriptional cycling has been 
reported previously for other NR-activated genes (Métivier et al., 2003; Kim et al., 2005; 
Degenhardt et al., 2009; Saramäki et al., 2009). Cycling is the result from cyclical 
association of NRs, their CoAs and CoRs with chromatin. In this study, 1α,25(OH)2D3 
treatment resulted in VDR association in a cyclical fashion with both VDRE regions on the 
IGFBP3 promoter. HDAC4 association was also cyclical on RE1/2, but in a different 
phase than VDR, being lowest when VDR association is peaking. In addition, at RE1/2 
chromatin activation corresponds with mRNA accumulation. These results suggest that 
RE1/2 has probably a more important role in 1α,25(OH)2D3-mediated IGFBP3 mRNA 
cycling than RE3. 
 
Furthermore, histone acetylation levels appeared to be more complex with the natural 
ligand treatment than with Gemini. In general, histone acetylation is associated with 
transcriptional activation and deacetylation with transcriptional repression through changes 
in chromatin condensation (Grunstein, 1997). Therefore, stably increasing chromatin 
activation observed in both VDRE regions with Gemini treatment correlates with steady 
mRNA accumulation. 
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Transcriptional cycling can be divided in to three phases (Degenhardt et al., 2009). Firstly, 
in the deactivation phase, CoRs and HDACs associate with chromatin keeping it 
transcriptionally repressed. Secondly, in the activation phase, transcription factors and 
CoAs replace them. Finally, in the third, initiation phase, VDREs associate with RNA 
polymerase via mediator proteins resulting in mRNA synthesis. In this study, from the 
family of HDACs, only HDAC4 and HDAC6 were up-regulated by 1α,25(OH)2D3, but 
interestingly none of them responded to Gemini. Increased HDAC4 and HDAC6 
availability can cause an extended deactivation phase with 1α,25(OH)2D3 treatment. 
During the transcriptional process, a prolonged deactivation phase results in mRNA 
degradation, while there is no new mRNA synthesis. This results then in cycling of mRNA 
accumulation.  
 
Gemini is a synthetic VDR ligand and has a larger volume than 1α,25(OH)2D3, but is still 
able to fit to the LBP of the VDR (Molnár et al., 2006). In addition, Gemini has been 
shown to bind more efficiently to LBP than the natural ligand. This leads to prolonged 
activation phase. Furthermore, Gemini was not able to induce HDAC expression and 
therefore the cyclical deactivation phase may be shortened. As a result, mRNA synthesis 
phases are longer and deactivation phases are shorter, which leads to diminished mRNA 
cycling and more prominent mRNA induction due to more continuous mRNA synthesis.  
 
Interestingly, 1α,25(OH)2D3-mediated transcriptional cycling was abolished when HDAC4 
and HDAC6 expression was down-regulated by siRNA silencing. This supports the finding 
that these two HDACs are important components of the 1α,25(OH)2D3-induced 
transcriptional cycling. However, siRNA silencing does not change the total mRNA 
induction after 240 min ligand treatment and mRNA levels induced by both ligands 
remained at the levels of control transfections. This suggests that HDAC4 and HDAC6 are 
not the only mediators for diverse actions of these ligands, but stronger nature of VDR 
activation is still observed with Gemini. It should be noted that these ligands are physically 
different, and they also change conformation of VDR in a different fashion (Molnár et al., 
2006). Therefore these findings suggest that HDAC4 and HDAC6 are mediators of 
transcriptional cycling, but are not the only reason for the diverse nature of these ligands. 
 
However, HDAC4 and HDAC6 association into VDREs were not always congruent with 
observations of VDR recruitment and histone acetylation. In addition, HDAC6 association 
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with RE1/2 seemed to be more complex in response to Gemini, than in response to 
1α,25(OH)2D3. Due to high standard deviations the interpretation of these results is 
unclear. And the respective assay will be repeated. 
 
In conclusion, 1α,25(OH)2D3-mediated up-regulation of the IGFBP3 gene is an interactive 
process, where cyclical association of VDR, HDAC4, and HDAC6 with VDREs at the 
IGFBP3 promoter results in controlled and cyclical induction of mRNA expression. On the 
other hand, Gemini has far more potent and direct effect on the up-regulation of IGFBP3 
without the cyclical control of transcription. The simplified model illustrates the diverse 
actions of 1α,25(OH)2D3- and Gemini-induced transcription via the VDR; 
 
A                 1α,25(OH)2D3      B         Gemini 
 
Figure 13. Model for mRNA periodicity in response to 1α,25(OH)2D3 and Gemini. In response to 
1α,25(OH)2D3 (A) transcription is divided in three phases, which results in cycling of mRNA accumulation. 
In response to Gemini (B), the initiation phase is longer due to reduced deactivation phase. This results in 
more continuous mRNA accumulation. 
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